Eliem Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Seattle and Cambridge, United Kingdom. The company is dedicated to developing innovative therapies for chronic pain and neuropsychiatric conditions. Eliem operates in the life sciences sector, primarily targeting patients who suffer from debilitating conditions that lack effective treatment options. The company's business model revolves around extensive research and development (R&D) to create novel pharmaceutical solutions. Eliem generates revenue through partnerships, licensing agreements, and potential future sales of its proprietary drugs. The company recently announced an agreement to acquire Tenet Medicines, Inc., and a concurrent $120 million private placement of common stock with a syndicate of institutional life science investors. This acquisition aims to advance TNT119, an anti-CD19 antibody designed for treating a broad range of autoimmune diseases.

Keywords: clinical-stage, biotechnology, chronic pain, neuropsychiatric, therapies, life sciences, R&D, pharmaceutical, autoimmune diseases, acquisition.